AAV9 Purification via Alkaline Anion Exchange Chromatography
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying recombinant adeno-associated virus (rAAV) particles are not scalable and do not meet good manufacturing practices, particularly for separating pharmacologically active full rAAV particles from genome-deficient empty capsids.
Innovation Solution
A scalable method using fast performance liquid chromatography (FPLC) with a strong anion exchange resin at pH 10.2 and a salt gradient to separate full AAV9 viral particles from empty intermediates, followed by affinity capture and anion exchange chromatography to achieve high purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional purification methods (cesium chloride gradient centrifugation, iodixanol gradient separation) are used, then rAAV particles can be purified, but the methods are not scalable and do not meet good manufacturing practices
Solution Approach 1:
The invention changes the pH parameter to alkaline conditions (pH 10.2) and uses a strong anion exchange resin with specific binding characteristics. This parameter change enables the resin to selectively bind full rAAV particles while allowing empty capsids to pass through, achieving both high purification quality and scalability that traditional gradient methods cannot provide
Solution Approach 2:
The invention replaces the mechanical centrifugation-based gradient separation system with a chromatography system using anion exchange resin. This substitution eliminates the limitations of gradient methods (low scalability, complex procedures) while maintaining high purification effectiveness through chemical affinity-based separation
2Manufacturing precision
If anion-exchange chromatography is used with rAAV capsid serotypes 1, 4, 5, and 8, then purification can be achieved, but the capsids bind weakly to anionic resins requiring combination with other methods like iodixinol density-gradient centrifugation
Solution Approach 1:
The invention changes the pH parameter to alkaline conditions (pH 10.2), which fundamentally alters the binding characteristics of the anion exchange resin. At this elevated pH, the strong anion exchange resin exhibits enhanced binding affinity for AAV9 capsids, allowing single-step purification without requiring combination with density-gradient centrifugation or other additional methods
Solution Approach 2:
The invention makes the anion exchange resin universally effective for AAV9 purification across a broad range of conditions at alkaline pH. The resin can handle various input materials (cell lysates, supernatants) and achieves consistent high-purity results in a single step, eliminating the need for multiple specialized methods
3Productivity
If cells are lysed to release rAAV particles and maximize yield, then production yield is improved, but the cell lysate contains various cellular components (host cell DNA, proteins, media components) that must be separated
Solution Approach 1:
The invention extracts and removes harmful cellular components (host cell DNA, proteins, media components) from the cell lysate in a single purification step. The strong anion exchange resin at pH 10.2 selectively binds full rAAV particles while allowing contaminants to pass through in the flow-through, achieving both high yield retention and effective contamination removal
Solution Approach 2:
The invention uses the strong anion exchange resin as an intermediary substance that mediates separation between the desired rAAV particles and harmful cellular components. The resin's specific binding properties at alkaline pH enable it to selectively interact with full capsids while excluding contaminants, facilitating efficient purification
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves at least 90% purification of full rAAV9 particles from empty capsids, reducing contamination to less than 5%, and is suitable for commercial-scale production.
Implementation Method 1
a scalable method using fast performance liquid chromatography (FPLC) with a strong anion exchange resin at pH 10.2 and a salt gradient to separate full AAV9 viral particles from empty intermediates
Implementation Method 2
followed by affinity capture and anion exchange chromatography to achieve high purity
Data Source
AI summary
A two-step chromatography purification scheme is described which selectively captures and isolates the genome-containing rAAV vector particles from the clarified, concentrated supernatant of a rAAV production cell culture. The process utilizes an affinity capture method performed at a high salt concentration followed by an anion exchange resin method performed at high pH to provide rAAV vector particles which are substantially free of rAAV intermediates.